JP2010187674A5 - - Google Patents

Download PDF

Info

Publication number
JP2010187674A5
JP2010187674A5 JP2010039568A JP2010039568A JP2010187674A5 JP 2010187674 A5 JP2010187674 A5 JP 2010187674A5 JP 2010039568 A JP2010039568 A JP 2010039568A JP 2010039568 A JP2010039568 A JP 2010039568A JP 2010187674 A5 JP2010187674 A5 JP 2010187674A5
Authority
JP
Japan
Prior art keywords
antibody
amyloid
disease
amyloidosis
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010039568A
Other languages
Japanese (ja)
Other versions
JP2010187674A (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2010187674A publication Critical patent/JP2010187674A/en
Publication of JP2010187674A5 publication Critical patent/JP2010187674A5/ja
Withdrawn legal-status Critical Current

Links

Claims (33)

任意の機能的に等価な抗体またはその機能的部分を含むモノクローナル抗体であって、アミロイド単量体ペプチド、特にβ-アミロイド単量体ペプチド、例えばAβ単量体ペプチド1〜39、1〜40、1〜41、1〜42、または1〜43、とりわけAβ1〜42単量体ペプチドなどとの共インキュベーションにより、Aβ単量体の高分子重合体原線維への凝集を抑制する、前記モノクローナル抗体。 A monoclonal antibody comprising any functionally equivalent antibody or functional part thereof, wherein the amyloid monomer peptide, in particular β-amyloid monomer peptide, for example Aβ monomer peptide 1-39, 1-40, 1～41,1～42 or 1-43, especially by co-incubation with such a [beta] 1 to 42 monomeric peptides, inhibits the aggregation of the high molecular polymer fibrils a [beta] monomers, said monoclonal antibody, .. 任意の機能的に等価な抗体またはその機能的部分を含む抗体であって、SEQ ID NO：7の軽鎖可変領域（LCVR）およびSEQ ID NO：8の重鎖可変領域（HCVR）のCDR領域を含む、前記抗体。An antibody comprising any functionally equivalent antibody or a functional portion thereof, wherein the CDR regions of the light chain variable region (LCVR) of SEQ ID NO:7 and the heavy chain variable region (HCVR) of SEQ ID NO:8 The antibody, which comprises: 任意の機能的に等価な抗体またはその機能的部分を含む抗体であって、SEQ ID NO：7のLCVRおよびSEQ ID NO：8のHCVRのエピトープ結合断片を含む、前記抗体。An antibody comprising any functionally equivalent antibody or functional portion thereof, comprising the epitope binding fragment of LCVR of SEQ ID NO:7 and HCVR of SEQ ID NO:8. モノクローナル抗体である、任意の機能的に等価な抗体またはその機能的部分を含む、請求項２または３記載の抗体。4. The antibody according to claim 2 or 3, comprising any functionally equivalent antibody or a functional part thereof which is a monoclonal antibody. LCVRが、SEQ ID NO：23のアミノ酸配列を有するLCVR CDR1と、SEQ ID NO：24のアミノ酸配列を有するLCVR CDR2と、SEQ ID NO：25のアミノ酸配列を有するLCVR CDR3とを含み、LCVR comprises LCVR CDR1 having the amino acid sequence of SEQ ID NO:23, LCVR CDR2 having the amino acid sequence of SEQ ID NO:24, and LCVR CDR3 having the amino acid sequence of SEQ ID NO:25,
HCVRが、SEQ ID NO：26のアミノ酸配列を有するHCVR CDR1と、SEQ ID NO：27のアミノ酸配列を有するHCVR CDR2と、SEQ ID NO：28のアミノ酸配列を有するHCVR CDR3とを含む、任意の機能的に等価な抗体またはその機能的部分を含む、請求項２〜４のいずれか一項記載の抗体。 Any function, wherein HCVR comprises HCVR CDR1 having the amino acid sequence of SEQ ID NO:26, HCVR CDR2 having the amino acid sequence of SEQ ID NO:27, and HCVR CDR3 having the amino acid sequence of SEQ ID NO:28 5. The antibody according to any one of claims 2 to 4, which comprises a biologically equivalent antibody or a functional portion thereof. LCVRもしくはHCVRまたはその両方、SEQ ID NO：7および8でそれぞれ提供されたペプチドのいずれかに対して相同なLCVRおよびHCVRを含む、任意の機能的に等価な抗体またはその機能的部分を含む、請求項2〜5のいずれか一項記載の抗体。 L CV R also properly is H CV R or both thereof, SEQ ID NO: including 7 and 8 homologous with respect to any of the peptides provided respectively L CV R Contact good beauty H CV R, optionally The antibody according to any one of claims 2 to 5, which comprises a functionally equivalent antibody or a functional portion thereof. LCVRが、SEQ ID NO：7で与えられた配列に対して90％、91％、92％、93％、94％、95％、96％、97％、98％、または99％同一なアミノ酸配列を有する、任意の機能的に等価な抗体またはその機能的部分を含む、請求項2〜5のいずれか一項記載の抗体。 L CV R is, SEQ ID NO: 7 90% relative to the sequence given in, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or a 99% identity The antibody according to any one of claims 2 to 5 , which comprises any functionally equivalent antibody having an amino acid sequence or a functional portion thereof. HCVRが、SEQ ID NO：8で与えられた配列に対して90％、91％、92％、93％、94％、95％、96％、97％、98％、または99％同一なアミノ酸配列を有する、任意の機能的に等価な抗体またはその機能的部分を含む、請求項2〜5のいずれか一項記載の抗体。 H CV R is, SEQ ID NO: 90% to the sequence given in 8, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or a 99% identity The antibody according to any one of claims 2 to 5 , which comprises any functionally equivalent antibody having an amino acid sequence or a functional portion thereof. LCVRおよびHCVRが共に、SEQ ID NO：7および8で与えられた配列に対して85％、86％、87％、88％、89％、90％、91％、92％、93％、94％、95％、96％、97％、98％、または99％同一なアミノ酸配列を有する、任意の機能的に等価な抗体またはその機能的部分を含む、請求項2〜5のいずれか一項記載の抗体。 L CV R Contact good beauty H CV R together, SEQ ID NO: 7 and 85% to the sequence given in 8, 86%, 87%, 88%, 89%, 90%, 91%, 92% , 93%, 94%, including 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence, any functionally equivalent antibody or functional parts thereof, according to claim 2-5 The antibody according to any one of 1 . 前記請求項のいずれかに記載の抗体をコードするヌクレオチド配列を含む、ポリヌクレオチド。A polynucleotide comprising a nucleotide sequence encoding the antibody of any of the preceding claims. 請求項10記載のポリヌクレオチドを含む、宿主細胞。A host cell comprising the polynucleotide of claim 10. 宿主細胞が細菌、昆虫細胞、または哺乳類細胞である、請求項11記載の宿主細胞。The host cell according to claim 11, wherein the host cell is a bacterium, an insect cell, or a mammalian cell. 請求項11または12に記載の宿主細胞を培養する段階を含む、単量体型、オリゴマー型、またはポリマー型のアミロイドβに特異的に結合する抗体を産生する方法。A method for producing an antibody that specifically binds to monomeric, oligomeric, or polymeric amyloid β, comprising the step of culturing the host cell according to claim 11 or 12. 請求項1〜9のいずれか一項記載の任意の機能的に等価な抗体またはその機能的部分を含む抗体を治療的有効量で含む組成物。 Any functionally equivalent antibody or a composition comprising a therapeutically effective amount of an antibody comprising a functional portion thereof of any one of claims 1 to 9. 薬学的に許容される担体をさらに含む薬学的組成物である、請求項14記載の組成物。 A pharmaceutical composition comprising the al a pharmaceutically acceptable carrier The composition of claim 14,. アルツハイマー病に関与するAβタンパク質などのアミロイドタンパク質またはアミロイド様タンパク質と関連のある一群の疾患および障害であるアミロイドーシスを含む、アミロイドタンパク質もしくはアミロイド様タンパク質によって引き起こされるか、またはそれらと関連のある疾患および障害の治療で用いるための、請求項14または15記載の組成物。 Diseases and disorders caused by or associated with amyloid protein or amyloid-like proteins, including amyloidosis, which is a group of diseases and disorders associated with amyloid proteins or amyloid-like proteins such as Aβ proteins involved in Alzheimer's disease. 16. A composition according to claim 14 or 15 for use in the treatment of. 治療的有効量で、請求項1〜9のいずれか一項記載の任意の機能的に等価な抗体またはその機能的部分を含む抗体、ならびに任意で、さらなる生物活性物質、および／または薬学的に許容される担体および／または希釈剤および／または添加剤を含む混合物。 In a therapeutically effective amount of an antibody including any functionally equivalent antibody or functional parts thereof of any one of claims 1-9, and, optionally, further biologically active agents, and / or a pharmaceutically Mixtures containing acceptable carriers and/or diluents and/or additives. 金属キレート剤、ピレンゼピンおよび代謝産物、3-アミノ-1-プロパンスルホン酸（3APS）、1,3-プロパンジスルホナート（1,3PDS）、タウタンパク質、神経伝達物質、またはタクリン、リバスチグミン、ドネペジル、および／もしくはガランタミンなどのコリンエステラーゼ阻害薬（ChEI）、および他の薬物、ならびに栄養補給物質からなる群より選択される少なくとも1つの化合物を含む、請求項17記載の混合物。 Metallic chelating agent, pirenzepine and Metabolites thereof, 3-amino-1-propanesulfonic acid (3APS), 1,3-propanediol disulfonate (1,3PDS), data Utanpaku protein, neurotransmitter, was or tacrine , rivastigmine, donepezil, and / or cholinesterase inhibitors such as galantamine (ChEIs), and other drugs, and at least one compound selected from the group consisting of nutraceuticals, mixture of claim 17. アルツハイマー病（AD）、ならびに例えば、軽度認知障害（MCI）、レーヴィ小体認知症、ダウン症候群、アミロイドーシスを伴う遺伝性脳出血（オランダ型）；グアム・パーキンソン認知症複合；ならびに進行性核上麻痺、多発性硬化症などのアミロイド様タンパク質に基づくかまたは関連のある他の疾患；クロイツフェルト・ヤコブ病、パーキンソン病、HIV関連認知症、ALS（筋萎縮性側索硬化症）、封入体筋炎（IBM）、成人発症型糖尿病；老人性心アミロイドーシス；内分泌腫瘍、および黄斑変性症を含む他のものといった認知記憶能力の損失を特徴とする疾患または病状などの神経疾患を非限定的に含む疾患などの続発性アミロイドーシスおよび加齢性アミロイドーシスを含んだ、アミロイド斑形成と関連のある一群の疾患および障害であるアミロイドーシスを治療するためまたはその影響を緩和するための薬物の調製のための、請求項1〜8のいずれか一項記載のモノクローナル抗体および／もしくはその機能的部分、または請求項14〜16のいずれか一項記載の組成物、または請求項17または18記載の混合物、の使用。 Alzheimer's disease (AD), and, for example, mild cognitive impairment (MCI), Lewy body dementia, Down syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type); Guam Parkinson dementia complex; and progressive supranuclear palsy, Other diseases based on or related to amyloid-like proteins such as multiple sclerosis; Creutzfeldt-Jakob disease, Parkinson's disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), inclusion body myositis (IBM ), adult-onset diabetes mellitus; senile cardiac amyloidosis; endocrine tumors, and diseases including, but not limited to, neurological disorders such as conditions characterized by loss of cognitive memory capacity such as macular degeneration and other conditions. including secondary amyloidosis and age-related amyloidosis, for the preparation of a medicament for alleviating or for the effects of treating amyloidoma shea scan a group of diseases and disorders that are associated with amyloid plaque formation, claim 1 monoclonal antibodies and / or functional part thereof according to any one claim of 1-8 or any one claim set composition as claimed in claim 14 to 16 or claim 17 or 18 mixtures described, the use of. アルツハイマー病（AD）、ならびに例えば、軽度認知障害（MCI）、レーヴィ小体認知症、ダウン症候群、アミロイドーシスを伴う遺伝性脳出血（オランダ型）；グアム・パーキンソン認知症複合；ならびに進行性核上麻痺、多発性硬化症などのアミロイド様タンパク質に基づくかまたは関連のある他の疾患；クロイツフェルト・ヤコブ病、パーキンソン病、HIV関連認知症、ALS（筋萎縮性側索硬化症）、封入体筋炎（IBM）、成人発症型糖尿病；老人性心アミロイドーシス；内分泌腫瘍、および黄斑変性症を含む他のものといった認知記憶能力の損失を特徴とする疾患または病状などの神経疾患を非限定的に含む疾患などの続発性アミロイドーシスおよび加齢性アミロイドーシスを含んだ、アミロイド斑形成と関連のある一群の疾患および障害であるアミロイドーシスの治療またはその影響を緩和において使用するための、請求項1〜9のいずれか一項記載の薬学的組成物、または請求項14〜16のいずれか一項記載の組成物、または請求項17または18記載の混合物、の調製方法であって、該抗体を薬学的に許容される形態に製剤化する段階を含む、前記方法。 Alzheimer's disease (AD) and, for example, mild cognitive impairment (MCI), Lewy body dementia, Down syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type); Guam Parkinson dementia complex; and progressive supranuclear palsy, Other diseases based on or related to amyloid-like proteins such as multiple sclerosis; Creutzfeldt-Jakob disease, Parkinson's disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), inclusion body myositis (IBM ), adult-onset diabetes mellitus; senile cardiac amyloidosis; endocrine tumors, and diseases including, but not limited to, neurological disorders such as conditions or conditions characterized by loss of cognitive memory capacity such as macular degeneration. including secondary amyloidosis and age-related amyloidosis, for use in alleviating the treatment or the effects of amyloid over sheet scan a group of diseases and disorders that are associated with amyloid plaque formation, any of claims 1 to 9 one the pharmaceutical composition of claim wherein, or composition of any one of claims 14 to 16, or claim 17 or 18 mixtures according to a temper made how, pharmaceutically acceptable to the antibody Said method comprising the step of formulating into a form as described . アミロイド関連疾患または病状に罹患した動物、特に哺乳動物、とりわけヒトの脳内の斑負荷を減らす、斑量を減らす際に、もしくは量を減らす際に使用するため；または
アミロイド関連疾患または病状に罹患した動物、特に哺乳動物、とりわけヒトの脳内の斑量を減らすための、請求項14または15記載の組成物。 For use in reducing, or in reducing the amount of plaque in the brain of an animal, especially a mammal, especially a human, suffering from an amyloid-related disease or condition ; or
16. A composition according to claim 14 or 15 for reducing the amount of plaque in the brain of an animal, especially a mammal, especially a human suffering from an amyloid-related disease or condition . アミロイド関連疾患または病状に罹患した動物、特に哺乳動物、とりわけヒトの脳内の可溶性Aβの総量を減少させる際に使用するための、請求項14または15記載の組成物。 16. A composition according to claim 14 or 15 for use in reducing the total amount of soluble A[beta] in the brain of an animal, especially a mammal, especially a human suffering from an amyloid related disease or condition. アルツハイマー病（AD）、ならびに例えば、軽度認知障害（MCI）、レーヴィ小体認知症、ダウン症候群、アミロイドーシスを伴う遺伝性脳出血（オランダ型）；グアム・パーキンソン認知症複合；ならびに進行性核上麻痺、多発性硬化症などのアミロイド様タンパク質に基づくかまたは関連のある他の疾患；クロイツフェルト・ヤコブ病、パーキンソン病、HIV関連認知症、ALS（筋萎縮性側索硬化症）、封入体筋炎（IBM）、成人発症型糖尿病；老人性心アミロイドーシス；内分泌腫瘍、および黄斑変性症を含む他のものといった認知記憶能力の損失を特徴とする疾患または病状などの神経疾患を非限定的に含む疾患などの続発性アミロイドーシスおよび加齢性アミロイドーシスを含んだ、アミロイド斑形成と関連のある一群の疾患および障害であるアミロイドーシスを予防する、治療する、またはその影響を緩和するための、請求項14または15記載の組成物。 Alzheimer's disease (AD) and, for example, mild cognitive impairment (MCI), Lewy body dementia, Down syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type); Guam Parkinson dementia complex; and progressive supranuclear palsy, Other diseases based on or related to amyloid-like proteins such as multiple sclerosis; Creutzfeldt-Jakob disease, Parkinson's disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), inclusion body myositis (IBM ), adult-onset diabetes mellitus; senile cardiac amyloidosis; endocrine tumors, and diseases including, but not limited to, neurological disorders such as conditions or conditions characterized by loss of cognitive memory capacity such as macular degeneration. including secondary amyloidosis and age-related amyloidosis, amyloidosis is a group of diseases and disorders that are associated with amyloid plaque formation for prevention, treatment, or to mitigate its effects, according to claim 14 or 15, wherein Composition . アミロイドに関連した疾患または病状を呈している哺乳動物における認知記憶能力を保持または向上させる際に使用するための、請求項14または15記載の組成物。 16. The composition of claim 14 or 15 for use in maintaining or enhancing cognitive memory capacity in a mammal exhibiting a disease or condition associated with amyloid. 請求項1〜9のいずれか一項記載の抗体を産生するという点で特徴づけられるハイブリドーマ細胞株。 A hybridoma cell line characterized in that it produces the antibody of any one of claims 1-9. 試料中のアミロイドタンパク質のエピトープに対する抗体またはその活性断片の免疫特異的結合を検出することを含む、患者におけるアミロイドに関連した疾患または病状の診断の方法であって、
（a）アミロイド抗原を含むことが疑われる試料を、請求項1〜9のいずれか一項記載の抗体と接触させる段階であって、該抗体がアミロイドタンパク質のエピトープと結合する、前記段階；
（b）抗体をアミロイド抗原と結合させて、免疫複合体を形成させる段階；
（c）免疫複合体の形成を検出する段階；ならびに
（d）試料における、免疫複合体の有無とアミロイド抗原の有無とを相関づける段階
を含む、前記方法。 A method of diagnosing a disease or medical condition associated with amyloid in a patient, comprising detecting immunospecific binding of an antibody or an active fragment thereof to an epitope of amyloid protein in a sample , comprising:
(A) a specimen suspected of containing the amyloid antigen, a step of contacting the antibody of any one of claims 1-9, wherein the antibody binds an epitope of the amyloid protein, wherein said step;
(B) binding the antibody with an amyloid antigen to form an immune complex;
Step detecting the formation of (c) immune complexes; and definitive in (d) of specimen, comprising the steps of correlating the presence or absence of presence and amyloid antigen immune complexes, said method. 組織中のアミロイド生成斑の負荷（burden）の程度を決定する方法であって、
（a）調査中の組織を代表する試料を入手する段階；
（b）該試料を、請求項1〜9のいずれか一項記載の抗体を用いて、アミロイド抗原の存在に関して検査する段階；
（c）抗原と結合した抗体の量を決定する段階；および
（d）組織中の斑負荷を計算する段階
を含む、前記方法。 A method of determining the degree of burden of amyloidogenic plaques in a tissue, comprising:
(A) obtaining a sample representative of the tissue under investigation;
Step (b) said sample, and using the antibody of any one of claims 1-9, to check for the presence of amyloid antigen;
Step (c) determining the amount of antibody bound to the antigen; comprises calculating the plaque burden of and (d) in the tissue, said method. 段階(c）における免疫複合体の形成が、免疫複合体の有無がアミロイド抗原の有無と相関するように決定される、請求項26記載の方法。 27. The method of claim 26 , wherein the formation of immune complexes in step (c) is determined such that the presence or absence of immune complexes correlates with the presence or absence of amyloid antigen. 試料中のアミロイドタンパク質のエピトープに対する抗体またはその活性断片の免疫特異的結合を検出することを含む、患者におけるアミロイドに関連した疾患または病状に対する素因を診断するための方法であって、
（a）アミロイド抗原を含むことが疑われる試料を、請求項1〜9のいずれか一項記載の抗体と接触させる段階であって、該抗体がアミロイドタンパク質のエピトープと結合する、段階；
（b）抗体をアミロイド抗原と結合させて、免疫複合体を形成させる段階；
（c）免疫複合体の形成を検出する段階；ならびに
（d）試料における、免疫複合体の有無とアミロイド抗原の有無とを相関づける段階；
（e）該免疫複合体の量を正常対照値と比較する段階、
を含み、該凝集物の量が正常対照値と比較して多いことにより、該患者がアミロイドに関連した疾患もしくは病状に、罹患しているかまたはそれを発症するリスクを有することが示される、前記方法。 Was Antibodies or to an epitope of the amyloid protein in a sample comprising detecting the immunospecific binding of an active fragment thereof, a method for diagnosing a predisposition to a disease or condition associated with amyloid in a patient,
The specimen suspected of containing (a) amyloid antigen, a step of contacting the antibody of any one of claims 1-9, wherein the antibody binds an epitope of the amyloid protein, stage;
(B) binding the antibody with an amyloid antigen to form an immune complex;
Step (c) detecting the formation of immune complexes; definitive to and (d) specimen, the step of correlating the presence or absence of presence and amyloid antigen immune complex;
(E) comparing the amount of said immune complex with a normal control value,
Comprises, by volume of the agglomerate is large compared to a normal control value, said patient with a disease or condition associated with amyloid, it is shown that at risk of developing or it suffering, the Method. 前記請求項のいずれか一項記載の抗体またはワクチン組成物による治療後の患者における微小残存病変(minimal residual disease)をモニタリングするための方法であって、
（a）アミロイド抗原を含むことが疑われる試料を、請求項1〜9のいずれか一項記載の抗体と接触させる段階であって、該抗体がアミロイドタンパク質のエピトープと結合する、前記段階；
（b）抗体をアミロイド抗原と結合させて、免疫複合体を形成させる段階；
（c）免疫複合体の形成を検出する段階；ならびに
（d）試料における、免疫複合体の有無とアミロイド抗原の有無とを相関づける段階；
（e）該免疫複合体の量を正常対照値と比較する段階
を含み、該凝集物の量が正常対照値と比較して多いことにより、該患者がさらに微小残存病変に罹患していることが示される、前記方法。 A method for monitoring minimal residual disease in a patient after treatment with the antibody or vaccine composition of any one of the preceding claims,
(A) a specimen suspected of containing the amyloid antigen, a step of contacting the antibody of any one of claims 1-9, wherein the antibody binds an epitope of the amyloid protein, wherein said step;
(B) binding the antibody with an amyloid antigen to form an immune complex;
Step (c) detecting the formation of immune complexes; definitive to and (d) specimen, the step of correlating the presence or absence of presence and amyloid antigen immune complex;
(E) comprising a step of comparing the amount of the immune complex with a normal control value, wherein the amount of the aggregate is larger than that of the normal control value, so that the patient further suffers from minimal residual disease It is indicated, the method. 前記請求項のいずれか一項記載の抗体またはワクチン組成物によって治療された患者の反応性を予測するための方法であって、
（a）アミロイド抗原を含むことが疑われる試料を、請求項1〜9のいずれか一項記載の抗体と接触させる段階であって、該抗体がアミロイドタンパク質のエピトープと結合する、前記段階；
（b）抗体をアミロイド抗原と結合させて、免疫複合体を形成させる段階；
（c）免疫複合体の形成を検出する段階；ならびに
（d）試料における、免疫複合体の有無とアミロイド抗原の有無とを相関づける段階；
（e）治療の開始の前および後の該免疫複合体の量を比較する段階
を含み、該凝集物の量が減少することにより、該患者が治療に反応する高い可能性を有することが示される、前記方法。 A method for predicting the responsiveness of a patient treated by the antibody or vaccine composition of any one of the preceding claims, comprising:
(A) a specimen suspected of containing the amyloid antigen, a step of contacting the antibody of any one of claims 1-9, wherein the antibody binds an epitope of the amyloid protein, wherein said step;
(B) binding the antibody with an amyloid antigen to form an immune complex;
Step (c) detecting the formation of immune complexes; definitive to and (d) specimen, the step of correlating the presence or absence of presence and amyloid antigen immune complex;
(E) comprising the step of comparing the amount of said immune complex before and after the start of the treatment, wherein the reduced amount of said aggregates indicates that said patient has a higher likelihood of responding to the treatment. The method described above . 請求項1〜9のいずれか一項記載の抗体を含む、アミロイドに関連した疾患および病状の検出および診断のための検査キット。 A test kit for detecting and diagnosing diseases and medical conditions related to amyloid, which comprises the antibody according to any one of claims 1 to 9 . アミロイド関連疾患または病状が以下からなる群から選択される、請求項21、22、および24のいずれか一項記載の組成物、または請求項26または29記載の方法：30. The composition of any one of claims 21, 22, and 24, or the method of claim 26 or 29, wherein the amyloid-related disease or condition is selected from the group consisting of:
アルツハイマー病（AD）、ならびに例えば、軽度認知障害（MCI）、レーヴィ小体認知症、ダウン症候群、アミロイドーシスを伴う遺伝性脳出血（オランダ型）；グアム・パーキンソン認知症複合；ならびに進行性核上麻痺、多発性硬化症などのアミロイド様タンパク質に基づくかまたは関連のある他の疾患；クロイツフェルト・ヤコブ病、パーキンソン病、HIV関連認知症、ALS（筋萎縮性側索硬化症）、封入体筋炎（IBM）、成人発症型糖尿病；老人性心アミロイドーシス；内分泌腫瘍、および黄斑変性症を含む他のものといった認知記憶能力の損失を特徴とする疾患または病状などの神経疾患を非限定的に含む疾患などの続発性アミロイドーシスおよび加齢性アミロイドーシスを含んだ、アミロイド斑形成と関連のある一群の疾患および障害であるアミロイドーシス。 Alzheimer's disease (AD), and, for example, mild cognitive impairment (MCI), Lewy body dementia, Down syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type); Guam Parkinson dementia complex; and progressive supranuclear palsy, Other diseases based on or related to amyloid-like proteins such as multiple sclerosis; Creutzfeldt-Jakob disease, Parkinson's disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), inclusion body myositis (IBM ), adult-onset diabetes mellitus; senile cardiac amyloidosis; endocrine tumors, and diseases including, but not limited to, neurological disorders such as conditions or conditions characterized by loss of cognitive memory capacity such as macular degeneration. Amyloidosis, a group of diseases and disorders associated with amyloid plaque formation, including secondary amyloidosis and age-related amyloidosis.
JP2010039568A 2005-12-12 2010-02-25 beta1-42 SPECIFIC MONOCLONAL ANTIBODY HAVING THERAPEUTIC CHARACTERISTIC Withdrawn JP2010187674A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027092 2005-12-12
EP06014729 2006-07-14
EP06020766 2006-10-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008544834A Division JP5419131B2 (en) 2005-12-12 2006-12-08 Β1-42 specific monoclonal antibodies with therapeutic properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013216451A Division JP2014039561A (en) 2005-12-12 2013-10-17 β 1 TO 42 SPECIFIC MONOCLONAL ANTIBODY HAVING THERAPEUTIC PROPERTY

Publications (2)

Publication Number Publication Date
JP2010187674A JP2010187674A (en) 2010-09-02
JP2010187674A5 true JP2010187674A5 (en) 2012-03-29

Family

ID=37896141

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008544834A Active JP5419131B2 (en) 2005-12-12 2006-12-08 Β1-42 specific monoclonal antibodies with therapeutic properties
JP2010039568A Withdrawn JP2010187674A (en) 2005-12-12 2010-02-25 beta1-42 SPECIFIC MONOCLONAL ANTIBODY HAVING THERAPEUTIC CHARACTERISTIC
JP2013216451A Withdrawn JP2014039561A (en) 2005-12-12 2013-10-17 β 1 TO 42 SPECIFIC MONOCLONAL ANTIBODY HAVING THERAPEUTIC PROPERTY
JP2016004910A Active JP6174727B2 (en) 2005-12-12 2016-01-14 Β1-42 specific monoclonal antibodies with therapeutic properties
JP2017069675A Ceased JP2017153480A (en) 2005-12-12 2017-03-31 Aβ1-42 SPECIFIC MONOCLONAL ANTIBODIES HAVING THERAPEUTIC PROPERTIES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008544834A Active JP5419131B2 (en) 2005-12-12 2006-12-08 Β1-42 specific monoclonal antibodies with therapeutic properties

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013216451A Withdrawn JP2014039561A (en) 2005-12-12 2013-10-17 β 1 TO 42 SPECIFIC MONOCLONAL ANTIBODY HAVING THERAPEUTIC PROPERTY
JP2016004910A Active JP6174727B2 (en) 2005-12-12 2016-01-14 Β1-42 specific monoclonal antibodies with therapeutic properties
JP2017069675A Ceased JP2017153480A (en) 2005-12-12 2017-03-31 Aβ1-42 SPECIFIC MONOCLONAL ANTIBODIES HAVING THERAPEUTIC PROPERTIES

Country Status (32)

Country Link
US (5) US7772375B2 (en)
EP (3) EP2361638B1 (en)
JP (5) JP5419131B2 (en)
KR (4) KR20150098683A (en)
AR (1) AR058326A1 (en)
AU (1) AU2006326284B2 (en)
BR (1) BRPI0619748B8 (en)
CA (1) CA2632822C (en)
CL (1) CL2011000010A1 (en)
CR (3) CR9995A (en)
CY (1) CY1115014T1 (en)
DK (1) DK2361638T3 (en)
EC (1) ECSP088530A (en)
ES (1) ES2454253T3 (en)
HK (2) HK1161141A1 (en)
HR (2) HRP20140251T1 (en)
IL (6) IL191230A (en)
MA (1) MA30163B1 (en)
MX (2) MX358175B (en)
MY (1) MY167887A (en)
NO (1) NO345996B1 (en)
NZ (1) NZ568012A (en)
PH (1) PH12011502389B1 (en)
PL (1) PL2361638T3 (en)
PT (1) PT2361638E (en)
RS (1) RS53291B (en)
RU (2) RU2015111675A (en)
SG (1) SG10201404801YA (en)
SI (1) SI2361638T1 (en)
TW (2) TWI508975B (en)
WO (1) WO2007068412A2 (en)
ZA (1) ZA200804916B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7745569B2 (en) * 2003-04-07 2010-06-29 The Regents Of The University Of California Amyloid specific binding peptides and detecting abeta peptide
CN101506236B (en) † 2005-11-30 2012-12-12 雅培制药有限公司 Monoclonal antibodies against amyloid beta protein and uses thereof
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2015111675A (en) 2005-12-12 2015-08-10 Ац Иммуне Са SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES
CN101330923B (en) 2005-12-12 2015-01-07 Ac免疫有限公司 Therapeutic vaccine
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
EP3988566A1 (en) * 2006-07-14 2022-04-27 AC Immune SA Humanized antibody against amyloid beta
AR062065A1 (en) * 2006-07-14 2008-10-15 Ac Immune Sa HUMANIZED ANTIBODY
TWI608014B (en) * 2006-07-14 2017-12-11 Ａｃ免疫公司 Anti-beta-amyloid antibodies or antigen-binding fragments thereof, the use and method of use thereof
KR20150002879A (en) * 2006-10-02 2015-01-07 에이씨 이뮨 에스.에이. Humanized antibody against amyloid beta
JP5292300B2 (en) 2006-11-24 2013-09-18 エーシー イミューン ソシエテ アノニム N- (methyl) -1H-pyrazol-3-amine derivatives, N- (methyl) -pyridin-2-amine derivatives, and N for the treatment of diseases related to amyloid or amyloid-like proteins such as Alzheimer's disease -(Methyl) -trizol-2-amine derivatives
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN103408661B (en) 2007-01-05 2016-04-06 苏黎世大学 The method of disease-specific binding molecules and target is provided
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
US8323654B2 (en) * 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
MX2009013505A (en) * 2007-06-12 2010-01-27 Ac Immune Sa Humanized antibodies to amyloid beta.
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
CN101883790B (en) * 2007-10-05 2015-09-09 基因技术公司 The purposes of anti-amyloid beta antibody in illness in eye
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
JPWO2009104736A1 (en) * 2008-02-22 2011-06-23 田平　武 Tissue amyloid plaque affinity antibody and pharmaceutical composition using the same
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
AU2009240470B8 (en) * 2008-04-25 2015-02-05 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
AT509611B1 (en) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh VACCINE
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
PL2949666T3 (en) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Human anti-alpha-synuclein antibodies
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
MX2012002993A (en) 2009-09-11 2012-04-19 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase.
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
CN102051407B (en) * 2009-11-09 2012-12-12 中国医学科学院医药生物技术研究所 Screening method of human immunodeficiency virus-1 (HIV-1) precursor protein pre-maturation inducer
PE20130527A1 (en) 2010-03-03 2013-05-09 Boehringer Ingelheim Int BIPARATOPIC A-BETA BINDING POLYPEPTIDES
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
MX2012010470A (en) 2010-03-10 2012-10-09 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
KR101851810B1 (en) 2010-04-16 2018-04-26 에이씨 이뮨 에스.에이. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
RU2607368C2 (en) 2010-07-30 2017-01-10 Ац Иммуне С.А. Safe and functional humanized antibodies
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
WO2012036786A1 (en) * 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
EP2632434A1 (en) 2010-10-26 2013-09-04 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
KR102099462B1 (en) 2010-11-30 2020-04-10 제넨테크, 인크. Low affinity blood brain barrier receptor antibodies and uses therefor
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
AR085302A1 (en) 2011-02-24 2013-09-18 Sanofi Sa METHOD OF PRODUCTION OF STIRATED ANTIBODIES
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
SI2723379T1 (en) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
ES2496341T3 (en) * 2011-10-04 2014-09-18 Affiris Ag Procedure to detect Aβ-specific antibodies in a biological sample
US9610326B2 (en) * 2011-10-17 2017-04-04 The Board Of Trustees Of The Leland Stanford Junior University Amyloid beta peptides as therapy for multiple sclerosis
EP2785364B1 (en) * 2011-11-29 2019-01-09 Proclara Biosciences, Inc. Use of p3 of bacteriophage as amyloid binding agents
JP6419068B2 (en) 2012-05-21 2018-11-07 ジェネンテック， インコーポレイテッド Methods for improving the safety of blood-brain barrier transport
CA2877516A1 (en) * 2012-07-03 2014-01-03 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
US9429584B2 (en) * 2013-02-28 2016-08-30 National Cancer Center Antibody against insoluble fibrin
WO2014189973A2 (en) 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
RU2016107435A (en) 2013-09-13 2017-10-18 Дженентек, Инк. COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS
WO2015038888A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
RU2724190C2 (en) * 2014-02-08 2020-06-23 Дженентек, Инк. Methods of treating alzheimer's disease
JP6779876B2 (en) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド Anti-transferrin receptor antibody and how to use it
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
CN107849105B (en) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 TAU binding antibodies
WO2018018031A1 (en) * 2016-07-22 2018-01-25 New York University Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
US10385096B2 (en) * 2016-08-30 2019-08-20 Council Of Scientific & Industrial Research Pro-Amb reverse turn restricted bioactive peptide analogues
US11397188B2 (en) * 2017-03-30 2022-07-26 Board Of Regents, The University Of Texas System Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
EA202090555A1 (en) 2017-08-22 2020-06-08 Байоджен Ма Инк. PHARMACEUTICAL COMPOSITIONS CONTAINING BETA AMYLOID ANTIBODIES
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CA3100896C (en) * 2018-05-30 2023-08-29 National Health Research Institutes Anti-abeta antibodies and uses thereof
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
US20230027014A1 (en) * 2019-11-12 2023-01-26 Ambetex Pty Ltd Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
CN113057963B (en) * 2021-03-31 2022-05-20 华中科技大学 Specific capture carrier for eliminating beta-amyloid and application thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5525339A (en) 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
DE3702789A1 (en) 1987-01-30 1988-08-18 Bayer Ag PROCUREMENT PROTEIN OF APC POLYPEPTIDE, FOR CODING DNA AND DIAGNOSTIC USE OF DNA AND PROTEIN
CA1340802C (en) 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
JP3277211B2 (en) 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド Test and treatment methods for Alzheimer's disease
US20010029293A1 (en) 1992-01-27 2001-10-11 Icos Corporation Icam-related protein
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
US5538845A (en) 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5891623A (en) 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
ZA938243B (en) 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE69432629T3 (en) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. ANTIBODIES AGAINST BETA AMYLOID OR DERIVATIVES AND ITS USE
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
EP0729976A1 (en) * 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
US5626332A (en) * 1994-07-29 1997-05-06 Harris Corporation Vibration isolation system using plural signals for control
BR9509421A (en) 1994-10-21 1997-09-30 Innogenetics Nv New hepatitis C virus genotype sequences and use as therapeutic and diagnostic prophylactic agents
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1996040731A1 (en) * 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
JPH09178743A (en) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd Determinationof soluble app
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
IT1293511B1 (en) 1997-07-30 1999-03-01 Gentili Ist Spa MONOCLONAL CATALYTIC ANTIBODIES WITH PROTEASIC ACTIVITY FOR THE SELECTIVE LYSIS OF THE PROTEIN COMPONENT OF PLATES AND RELATED AGGREGATES
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
CN101670105B (en) * 2000-02-24 2014-08-06 华盛顿大学 Humanized antibodies chelated with amylord beta peptide
EP1130032A1 (en) 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
US6664442B2 (en) 2000-03-30 2003-12-16 Elan Pharmaceuticals, Inc. Selecting compounds to reduce inflammation associated with Alzheimer's disease
US7371365B2 (en) 2000-04-04 2008-05-13 Mayo Foundation For Medical Education And Research Methods for detecting parenchymal plaques in vivo
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DE60139788D1 (en) 2000-09-06 2009-10-15 Aventis Pharma Sa METHODS AND COMPOSITIONS FOR AMYLOIDOSIS-ASSOCIATED DISEASES
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US20040191264A1 (en) 2001-02-19 2004-09-30 Nielsen Klaus Gregorius Synthetic vaccine agents
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
DE60230736D1 (en) 2001-04-30 2009-02-26 Lilly Co Eli HUMANIZED ANTIBODIES WHICH RECOGNIZE THE BETA AMYLOID PEPTIDE &x9;
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
DE50103881D1 (en) 2001-06-12 2004-11-04 Wiltfang Jens Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa
US6638722B2 (en) * 2001-06-13 2003-10-28 Invitrogen Corporation Method for rapid amplification of DNA
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
CN1396183A (en) 2001-07-13 2003-02-12 张小如 Human fusion antibody for reducing cerebral amyloid fibers associated with senile dementia
JP4729717B2 (en) 2001-08-03 2011-07-20 株式会社医学生物学研究所 Antibody that recognizes GM1 ganglioside-binding amyloid β protein, and DNA encoding the antibody
US20040241164A1 (en) 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
WO2003015691A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
DK1944040T3 (en) 2001-08-17 2012-10-29 Univ Washington Method of analysis for Alzheimer's disease
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
CN100488982C (en) * 2001-11-02 2009-05-20 迪尔基因国际有限公司 Methods of preparing monoclonal antibodies binding with beta-amyloid proteins and bringing the protein configuration conversion
EP1975179A1 (en) 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
MXPA04010255A (en) 2002-04-19 2008-03-04 Univ Toronto Immunological methods and compositions for the treatment of alzheimer's disease.
WO2003090772A1 (en) 2002-04-25 2003-11-06 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
US8871447B2 (en) 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US20070213512A1 (en) 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10256900A1 (en) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumor-specific recognition molecules
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
CA2511599A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AT413945B (en) 2003-01-14 2006-07-15 Mattner Frank Dr Use of a compound having a binding capacity to an antibody specific for the natural N-terminal AB42 sequence, for preparing a vaccine for preventing and treating Alzheimer's disease
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
WO2004069182A2 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
WO2005028511A2 (en) 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
EP1469312A1 (en) 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease
US20040223912A1 (en) 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
ES2246105B1 (en) 2003-05-08 2007-03-01 Araclon Biotech, S.L. USE OF ANTIBODIES FOR THE TREATMENT OF AMYLOID DISEASES.
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
US20050124016A1 (en) 2003-08-01 2005-06-09 Enh Research Institute Antibodies specific for toxic amyloid beta protein oligomers
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
JP2007527865A (en) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloid formed from proteins with various sequences
CA2542084A1 (en) 2003-10-14 2005-04-28 University Of South Florida A method for the separation anti-amyloid beta antibody with amyloid beta peptide
JP4870348B2 (en) 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス Antibody acquisition and antigen identification against cell surface antigens
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
PL1720909T3 (en) 2004-02-23 2012-04-30 Lilly Co Eli Anti-abeta antibody
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008513732A (en) 2004-07-02 2008-05-01 ノースウエスタン ユニバーシティ Monoclonal antibody targeting pathological assembly of amyloid β (Abeta)
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
MX2007000998A (en) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same.
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
WO2006039470A2 (en) 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
CA2584859C (en) 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
EP1813947A4 (en) 2004-10-28 2008-06-11 Sanko Junyaku Kk Method of examining alzheimer's disease and diagnostic reagent
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
PE20061401A1 (en) 2004-12-15 2006-12-23 Neuralab Ltd Aß ANTIBODIES TO IMPROVE COGNITION
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
KR20080021585A (en) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
ES2259270B1 (en) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas IN VITRO DIAGNOSTIC METHOD OF ALZHEIMER'S DISEASE BY A MONOCLONAL ANTIBODY.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
JP2007077103A (en) 2005-09-16 2007-03-29 Yokohama City Univ Prophylactic or therapeutic agent for alzheimer's disease
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN101506236B (en) 2005-11-30 2012-12-12 雅培制药有限公司 Monoclonal antibodies against amyloid beta protein and uses thereof
US8263558B2 (en) 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
RU2015111675A (en) * 2005-12-12 2015-08-10 Ац Иммуне Са SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES
US7427342B2 (en) 2006-06-02 2008-09-23 General Electric Company Method and apparatus for shifting current distribution in electrodeionization systems
WO2008008463A2 (en) 2006-07-14 2008-01-17 Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
AR062065A1 (en) * 2006-07-14 2008-10-15 Ac Immune Sa HUMANIZED ANTIBODY
KR20150002879A (en) 2006-10-02 2015-01-07 에이씨 이뮨 에스.에이. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PE20090329A1 (en) 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof

Similar Documents

Publication Publication Date Title
JP2010187674A5 (en)
Reichenbach et al. Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model
JP2016104026A5 (en)
RU2015111675A (en) SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES
TWI516500B (en) Monoclonal anti-beta-amyloid antibody
JP2010530227A5 (en)
RU2014118456A (en) PHOSPHOSPECIFIC ANTIBODIES RECOGNIZING TAU
JP2010505415A5 (en)
US9895429B2 (en) Antibodies that bind amyloid oligomers
JP2009519708A5 (en)
US20150315267A1 (en) A method of reducing brain amyloid plaques using anti-ab antibodies
RU2014144331A (en) HUMANIZED TAU ANTIBODY
JP2006508072A (en) Amyloid beta-derived diffusible ligands (ADDLs), ADDL substitutes, ADDL-binding molecules, and uses thereof
KR20110011596A (en) Treatment and prophylaxis of amyloidosis
JP2008524247A (en) Amyloid beta antibody for use in cognitive improvement
JP2012530055A (en) Immunological targeting method of pathological tau protein
JP2008513732A (en) Monoclonal antibody targeting pathological assembly of amyloid β (Abeta)
JP2012522754A5 (en)
RU2011144307A (en) PHARMACEUTICAL COMPOSITION
CN101325972B (en) A β 1-42 specific monoclonal antibody with therapeutic properties
US20120100129A1 (en) N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders
JP5474807B2 (en) Modified amyloid β peptide
WO2013012811A2 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20180134775A1 (en) Alpha-Synuclein Antibodies (7A11)
US20180134776A1 (en) Alpha-Synuclein Antibodies (4H6)